Who are Brimonidine 0.33%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Escitalopram+Mirtazapine, dexmedetomidine 1 µg/kg IV, mometasone furoate + Oxymetazoline, dexmedetomidine (IN), Dexmedetomidine 0.5 microgram/kg, Norepinephrine (Levophed).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brimonidine-0-33.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Brimonidine 0.33% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brimonidine 0.33% (Brimonidine 0.33%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist. Area: Dermatology.

marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Brimonidine 0.33% (Brimonidine 0.33%) — Derm Research, PLLC. Brimonidine is an alpha-2 adrenergic agonist that constricts blood vessels and reduces erythema (redness) in the skin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Brimonidine 0.33% TARGET	Brimonidine 0.33%	Derm Research, PLLC	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Escitalopram+Mirtazapine	Escitalopram+Mirtazapine	Ministry of Health & Welfare, Korea	marketed	Antidepressant combination (SSRI + NaSSA)	Serotonin transporter (SERT), norepinephrine transporter (NET), alpha-2 adrenergic receptors, histamine H1 receptors
dexmedetomidine 1 µg/kg IV	dexmedetomidine 1 µg/kg IV	American University of Beirut Medical Center	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
mometasone furoate + Oxymetazoline	mometasone furoate + Oxymetazoline	Guangzhou Women and Children's Medical Center	marketed	Intranasal corticosteroid + nasal decongestant combination	Glucocorticoid receptor (mometasone); alpha-2 adrenergic receptor (oxymetazoline)
dexmedetomidine (IN)	dexmedetomidine (IN)	Azienda Ospedaliera di Padova	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Dexmedetomidine 0.5 microgram/kg	Dexmedetomidine 0.5 microgram/kg	Sindh Institute of Urology and Transplantation	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Norepinephrine (Levophed)	Norepinephrine (Levophed)	University of Louisville	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist class)

USWM, LLC (dba US WorldMeds) · 2 drugs in this class
China International Neuroscience Institution · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
Eye Therapies, LLC · 1 drug in this class
Galderma R&D · 1 drug in this class
Guangzhou Women and Children's Medical Center · 1 drug in this class
Derm Research, PLLC · 1 drug in this class
Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 drug in this class
KK Women's and Children's Hospital · 1 drug in this class
American University of Beirut Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brimonidine 0.33% — Competitive Intelligence Brief. https://druglandscape.com/ci/brimonidine-0-33. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing